Resistance and cross-resistance with saqninavir and other HIV protease inhibitors: Theory and practice

AIDS

Volumn 12, Issue 5, 1998, Pages 453-460

  Roberts, Noel A ^a   Craig, J Charles ^a   Sheldon, Jonathan ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Cross resistance; Protease inhibitors; Resistance; Saquinavir

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

CROSS RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MUTATION; SAQUINAVIR; VIRUS REPLICATION;

EID: 0032568248     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199805000-00005     Document Type: Review

References (27)

1. Roberts JD, Bebenek K, Kunkel TA: The accuracy of reverse transcriptase from HIV-1. Science 1988, 242:1171-1173.
2. Ho DD, Neumann AU, Perelson AK, Wen C, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
3. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
4. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995, 267:483-489.
5. Jacobsen H, Hänggi M, Ott M, et al.: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996, 173:1379-1387.
6. Barrie KA, Perez EE, Lamers SL, et al.: Natural variations in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 1996, 219:407-416.
7. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high density oligonucleotide assays. Nature Med 1996, 2:753-754.
8. Lech WJ, Wang G, Yang YL, et al.: In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
9. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
10. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
11. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
12. Vasudevachari MB, Zhang Y-M, Imamichi H, Imamichi T, Falloon J, Salzman NP: Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob Agents Chemother 1996, 40:2535-2541.
13. Patick AK, Duran M, Cao Y, et al.: HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir are not cross-resistant to other protease inhibitors [abstract]. AIDS 1996, 10 (suppl 2):S18.
14. Partaledis JA, Yamaguchi K, Tisdale M, et al.: In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hyroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995, 69:5228-5235.
15. Jacobsen H, Yasargil K, Winslow DL, et al.: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995, 206:527-534.
16. Dianzani F, Antonelli G, Turrisiani O, Riva E, Dong G, Bellarosa D: In vitro selection of human immunodeficiency virus type 1 resistant to Ro 31-8959 proteinase inhibitor. Antiviral Chem Chemother 1993, 4:329-333.
17. Tisdale M, Meyers RE, Maschera B, et al.: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995, 39:1704-1710.
18. Maschera B, Furfine E, Blair ED: Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 1995, 69:5431-5436.
19. Roberts NA: Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 1995, 9 (suppl 2):S27-S32.
20. Sheldon J, Craig C, Race E, et al.: Reduced sensitivity to saquinavir (SQV) occurs infrequently, associates only with 48V or 90M and is modest in degree. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 599].
21. Race E, Sheldon JG, Rose J, et al.: Mutations associated with reduced sensitivity to saquinavir occur in a minority of patients treated in combination with ddC: results from a phase III clinical trial (NV 14256). Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 600].
22. Race E, Gilbert SM, Sheldon JG, Moffat AR, Tomlinson PW, Duncan IB: Low occurrence of reduced sensitivity to saquinavir in antiviral combination: results from a phase III clinical trial (NV14256). AIDS 1996, 10(suppl 2):S22.
23. Rose RE, Gong Y-F, Greytok JA, et al.: Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996, 93:1648-1653.
24. Salgo MP, Beattie D, Bragman K, et al.: Saquinavir (Invirase, SQV) vs Hivid (zalatabine, ddC) vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take Retrovir (zidovudine, ZDV). XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB410].
25. Nijhuis M, Schuurman R, Schipper P, et al.: Reduced replication potential of HIV-1 variants initially selected during ritonavir therapy is restored upon selection of additional substitutions. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 596].
26. Patick AK, Duran M, Cao Y, et al.: Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T or AZT and 3TC. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 10].
27. Waldholz M: Some AIDS cases defy new drug 'cocktails'. Wall Street Journal. 10 October 1996:B1.